Vestnik dermatologii i venerologiiVestnik dermatologii i venerologii0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov59310.25208/vdv593Research ArticleInfluence of combined drug tiladerm on the course of allergic contact dermatitis in ratsSMIRNOVV Svssmi@mail.ruSAVATEEVA-LJUBIMOVAT N-SAVATEEVA V-«CitoNIR» LtdInstitute of Toxicology of the Federal Medical and Biological Agency1510201389512413111032020Copyright © 2013, SMIRNOV V.S., SAVATEEVA-LJUBIMOVA T.N., SAVATEEV A.V.2013Materials and methods. The composition of glyzyrrhizic acid and glutamyl-tryptophane in the form of cream was studied using white rats. ACD was induced by application of the ethanol-acetone solution of 2,4-dinitrochlorobenzene (DNCB) during 4 days. The investigational drug was applied to the ACD lesions once a day during 14 consecutive days. The severity of ACD was assessed by the condition of the lesion focus, morphological composition of blood and apoptosis rate in the lesion. Results. It was shown that 4 days application of DNCB causes typical skin lesion manifesting in local papulovesicular eruptions, excoriations, and forming crust on the surface of the lesion. Application of the topical drug Tiladerm in the form of cream on the lesion induces significant acceleration of the lesion focus rehabilitation as early as on the end of 14 day of treatment. The activation of the markers of apoptosis (Ki-67, to a less extend p-53, caspase-3, Bcl-2) in the ACD lesion was shown. During treatment with Tiladerm, Ki-67 expression was reduced while expressions of p-53 and caspase-3 were enhanced. Conclusion. Thus, Tiladerm showed prominent positive effect on experimental ACD in rats.contact dermatitistreatmentglycyrrhizinic acidglutamyl-tryptophanmarkers of apoptosisконтактный дерматитлечениеТиладермглицирризиновая кислотаглутамил-триптофанмаркеры апоптоза[Эфрос Л.С., Горелик М.В. Химия и технология промежуточных продуктов. Л.: Химия; 1980][Куценко С.А. Основы токсикологии. СПб: Изд-во ВМА; 2002][Park H.Y., Park S.H., Yoon H.K. et al. Anti-allergic activity of 18-beta-glycyrrhetinic acid-3-O-beta-D-glucuronide. Arch Pharm Res 2004; 27: 57-60][Saeedi M., Morteza-Semnani K., Ghoreishi M.R. The treatment of atopic dermatitis with licorice gel. J Dermatol Treat 2003; 14: 153-157][Нечаева О.С., Смирнов В.С. Пептидные тимомиметики в комплексном лечении хронических аллергодерматозов. Росс. журн. кожн. и вен. болезней 2006; (4): 54-56][Смирнов В.С., Саватеева-Любимова Т.Н., Саватеев А.В. Влияние глицирризиновой кислоты, глутамил-триптофана и их комбинации на экспрессию маркеров апоптоза при аллергическом контактном дерматите у крыс. Вестник Уральской медицинской академической науки 2012; (4): 217-218][Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.; 2000][Public Health Service on Human Care and Use of Laboratory Animals. Washington - DC: US Department of Health and Human Services 1986; 28][Залкан П.М., Иевлева Е.А. Экспериментальная модель аллергического дерматита. Актуальные вопросы профессиональной дерматологии. М.; 1965. 106 с]